Answers are grounded in this paper and cite their sources.
New oral anticoagulants offer simpler management and reduced bleeding risk compared to warfarin.
新しい経口抗Xa 阻害薬をはじめとした抗凝固薬が日本でも発売され使用可能となっている．食事制限，モニター不要，半減期が短く薬効が速いなどの利点があり非常にシンプルな管理が可能である．また出血リスクもワルファリンの半分程度である．これらの新たな抗凝固薬の利点と潜在的な問題点を中心に最近の知見について述べる．
No takes yet. Share an insight, caveat, or question.
Hattori et al. (2014) conducted a review in Atrial fibrillation and venous thromboembolism. New oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) vs. Warfarin was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: